|
1
|
Fromigue O, Hamidouche Z, Vaudin P,
Lecanda F, Patino A, Barbry P, Mari B and Marie PJ: CYR61
downregulation reduces osteosarcoma cell invasion, migration, and
metastasis. J Bone Miner Res. 26:1533–1542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y, Zhang L, Zhang G, Li S, Duan J,
Cheng J, Ding G, Zhou C, Zhang J, Luo P, et al: Osteosarcoma
metastasis: Prospective role of ezrin. Tumour Biol. 35:5055–5059.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pompetti F, Rizzo P, Simon RM, Freidlin B,
Mew DJ, Pass HI, Picci P, Levine AS and Carbone M: Oncogene
alterations in primary, recurrent and metastatic human bone tumors.
J Cell Biochem. 63:37–50. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ladanyi M, Cha C, Lewis R, Jhanwar SC,
Huvos AG and Healey JH: MDM2 gene amplification in metastatic
osteosarcoma. Cancer Res. 53:16–18. 1993.PubMed/NCBI
|
|
5
|
Wang ZQ, Liang J, Schellander K, Wagner EF
and Grigoriadis AE: c-fos-induced osteosarcoma formation in
transgenic mice: Cooperativity with c-jun and the role of
endogenous c-fos. Cancer Res. 55:6244–6251. 1995.PubMed/NCBI
|
|
6
|
Cao Y, Jia SF, Chakravarty G, de
Crombrugghe B and Kleinerman ES: The osterix transcription factor
down-regulates interleukin-1 alpha expression in mouse osteosarcoma
cells. Mol Cancer Res. 6:119–126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cao Y, Zhou Z, de Crombrugghe B, Nakashima
K, Guan H, Duan X, Jia SF and Kleinerman ES: Osterix, a
transcription factor for osteoblast differentiation, mediates
antitumor activity in murine osteosarcoma. Cancer Res.
65:1124–1128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomas DM, Johnson SA, Sims NA, Trivett
MK, Slavin JL, Rubin BP, Waring P, McArthur GA, Walkley CR,
Holloway AJ, et al: Terminal osteoblast differentiation, mediated
by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol.
167:925–934. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Entz-Werlé N, Stoetzel C, Berard-Marec P,
Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone MD, Gentet
JC, Quillet R, et al: Frequent genomic abnormalities at TWIST in
human pediatric osteosarcomas. Int J Cancer. 117:349–355. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O'Farrill JS and Gordon N: Autophagy in
osteosarcoma. Adv Exp Med Biol. 804:147–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang P, Yang Y, Zweidler-McKay PA and
Hughes DP: Critical role of notch signaling in osteosarcoma
invasion and metastasis. Clin Cancer Res. 14:2962–2969. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khanna C, Wan X, Bose S, Cassaday R, Olomu
O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The
membrane-cytoskeleton linker ezrin is necessary for osteosarcoma
metastasis. Nat Med. 10:182–186. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fromigué O, Hamidouche Z and Marie PJ:
Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a
reductase sensitizes human osteosarcoma cells to anticancer drugs.
J Pharmacol Exp Ther. 325:595–600. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fromigué O, Hamidouche Z and Marie PJ:
Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces
osteosarcoma cell invasion. J Biol Chem. 283:30549–30556. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fromigué O, Haÿ E, Modrowski D, Bouvet S,
Jacquel A, Auberger P and Marie PJ: RhoA GTPase inactivation by
statins induces osteosarcoma cell apoptosis by inhibiting
p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell
differentiation. Cell Death Differ. 13:1845–1856. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang GP and Lau LF: Cyr61, product of a
growth factor-inducible immediate early gene, is associated with
the extracellular matrix and the cell surface. Cell Growth Differ.
2:351–357. 1991.PubMed/NCBI
|
|
17
|
Fromigue O, Lagneaux L and Body JJ:
Bisphosphonates induce breast cancer cell death in vitro. J Bone
Miner Res. 15:2211–2221. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Casey PJ and Seabra MC: Protein
prenyltransferases. J Biol Chem. 271:5289–5292. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McTaggart SJ: Isoprenylated proteins. Cell
Mol Life Sci. 63:255–267. 2006. View Article : Google Scholar
|
|
20
|
Hiraga T, Williams PJ, Mundy GR and Yoneda
T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231
human breast cancer cells in bone metastases. Cancer Res.
61:4418–4424. 2001.PubMed/NCBI
|
|
21
|
Lee MV, Fong EM, Singer FR and Guenette
RS: Bisphosphonate treatment inhibits the growth of prostate cancer
cells. Cancer Res. 61:2602–2608. 2001.PubMed/NCBI
|
|
22
|
Ory B, Heymann MF, Kamijo A, Gouin F,
Heymann D and Redini F: Zoledronic acid suppresses lung metastases
and prolongs overall survival of osteosarcoma-bearing mice. Cancer.
104:2522–2529. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sonnemann J, Eckervogt V, Truckenbrod B,
Boos J, Winkelmann W and van Valen F: The bisphosphonate
pamidronate is a potent inhibitor of human osteosarcoma cell growth
in vitro. Anticancer Drugs. 12:459–465. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Delarue FL, Adnane J, Joshi B, Blaskovich
MA, Wang DA, Hawker J, Bizouarn F, Ohkanda J, Zhu K, Hamilton AD,
et al: Farnesyltransferase and geranylgeranyltransferase I
inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT
association and histone acetylation of the RhoB promoter. Oncogene.
26:633–640. 2007. View Article : Google Scholar
|
|
25
|
Sebti SM and Hamilton AD:
Farnesyltransferase and geranylgeranyltransferase I inhibitors and
cancer therapy: Lessons from mechanism and bench-to-bedside
translational studies. Oncogene. 19:6584–6593. 2000. View Article : Google Scholar
|
|
26
|
Istvan E: Statin inhibition of HMG-CoA
reductase: A 3-dimensional view. Atheroscler Suppl. 4:3–8. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Farwell WR, Scranton RE, Lawler EV, Lew
RA, Brophy MT, Fiore LD and Gaziano JM: The association between
statins and cancer incidence in a veterans population. J Natl
Cancer Inst. 100:134–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Beri A, Sural N and Mahajan SB:
Non-atheroprotective effects of statins: A systematic review. Am J
Cardiovasc Drugs. 9:361–370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gonyeau MJ and Yuen DW: A clinical review
of statins and cancer: Helpful or harmful? Pharmacotherapy.
30:177–194. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Babic AM, Kireeva ML, Kolesnikova TV and
Lau LF: CYR61, a product of a growth factor-inducible immediate
early gene, promotes angiogenesis and tumor growth. Proc Natl Acad
Sci USA. 95:6355–6360. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bleau AM, Planque N and Perbal B: CCN
proteins and cancer: two to tango. Front Biosci. 10:998–1009. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Menéndez JA, Mehmi I, Griggs DW and Lupu
R: The angiogenic factor CYR61 in breast cancer: Molecular
pathology and therapeutic perspectives. Endocr Relat Cancer.
10:141–152. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jun JI and Lau LF: Taking aim at the
extracellular matrix: CCN proteins as emerging therapeutic targets.
Nat Rev Drug Discov. 10:945–963. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hall-Glenn F and Lyons KM: Roles for CCN2
in normal physiological processes. Cell Mol Life Sci. 68:3209–3217.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen CC and Lau LF: Functions and
mechanisms of action of CCN matricellular proteins. Int J Biochem
Cell Biol. 41:771–783. 2009. View Article : Google Scholar :
|
|
36
|
Holbourn KP, Acharya KR and Perbal B: The
CCN family of proteins: Structure-function relationships. Trends
Biochem Sci. 33:461–473. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leask A and Abraham DJ: All in the CCN
family: Essential matricellular signaling modulators emerge from
the bunker. J Cell Sci. 119:4803–4810. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kubota S and Takigawa M: The role of CCN2
in cartilage and bone development. J Cell Commun Signal. 5:209–217.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Martirosyan A, Clendening JW, Goard CA and
Penn LZ: Lovastatin induces apoptosis of ovarian cancer cells and
synergizes with doxorubicin: Potential therapeutic relevance. BMC
Cancer. 10:1032010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schmidmaier R, Baumann P, Bumeder I,
Meinhardt G, Straka C and Emmerich B: First clinical experience
with simvastatin to overcome drug resistance in refractory multiple
myeloma. Eur J Haematol. 79:240–243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
van der Spek E, Bloem AC, Sinnige HA and
Lokhorst HM: High dose simvastatin does not reverse resistance to
vincristine, adriamycin and dexamethasone (VAD) in myeloma.
Haematologica. 92:e130–e131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
van der Spek E, Bloem AC, van de Donk NW,
Bogers LH, van der Griend R, Kramer MH, de Weerdt O, Wittebol S and
Lokhorst HM: Dose-finding study of high-dose simvastatin combined
with standard chemotherapy in patients with relapsed or refractory
myeloma or lymphoma. Haematologica. 91:542–545. 2006.PubMed/NCBI
|
|
43
|
Marra M, Santini D, Meo G, Vincenzi B,
Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R,
et al: Cyr61 down-modulation potentiates the anticancer effects of
zoledronic acid in androgen-independent prostate cancer cells. Int
J Cancer. 125:2004–2013. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nguyen N, Kuliopulos A, Graham RA and
Covic L: Tumor-derived Cyr61(CCN1) promotes stromal matrix
metalloproteinase-1 production and protease-activated receptor
1-dependent migration of breast cancer cells. Cancer Res.
66:2658–2665. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Manara MC, Perbal B, Benini S, Strammiello
R, Cerisano V, Perdichizzi S, Serra M, Astolfi A, Bertoni F, Alami
J, et al: The expression of ccn3 (nov) gene in musculoskeletal
tumors. Am J Pathol. 160:849–859. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Perbal B, Zuntini M, Zambelli D, Serra M,
Sciandra M, Cantiani L, Lucarelli E, Picci P and Scotlandi K:
Prognostic value of CCN3 in osteosarcoma. Clin Cancer Res.
14:701–709. 2008. View Article : Google Scholar : PubMed/NCBI
|
